All Stories

  1. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan

    Article • Alimentary Pharmacology & Therapeutics, October 2018, Wiley

    Professor Tsai-Yuan Hsieh, Dr Chen-Hua Liu, Yi-Hsiang Huang

  2. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B

    Article • Journal of Gastroenterology and Hepatology, September 2018, Wiley

    Dr Chen-Hua Liu

  3. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection

    Article • Alimentary Pharmacology & Therapeutics, April 2018, Wiley

    Dr Chen-Hua Liu

  4. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

    Article • Journal of Gastroenterology and Hepatology, February 2018, Wiley

    Dr Chen-Hua Liu, Tung-Hung Su

  5. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients

    Article • Journal of Gastroenterology and Hepatology, December 2017, Wiley

    Dr Chen-Hua Liu, Tung-Hung Su

  6. Urgency to treat patients with chronic hepatitis C in Asia

    Article • Journal of Gastroenterology and Hepatology, April 2017, Wiley

    Dr Chen-Hua Liu

  7. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

    Article • International Journal of Nanomedicine, April 2014, Taylor & Francis

    Dr Chen-Hua Liu